GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Basilea Pharmaceutica Ltd (XSWX:BSLN) » Definitions » Debt-to-Revenue

Basilea Pharmaceutica (XSWX:BSLN) Debt-to-Revenue : 0.88 (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Basilea Pharmaceutica Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Basilea Pharmaceutica's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF17.5 Mil. Basilea Pharmaceutica's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF111.1 Mil. Basilea Pharmaceutica's annualized Revenue for the quarter that ended in Dec. 2023 was CHF145.5 Mil. Basilea Pharmaceutica's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.88.


Basilea Pharmaceutica Debt-to-Revenue Historical Data

The historical data trend for Basilea Pharmaceutica's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Basilea Pharmaceutica Debt-to-Revenue Chart

Basilea Pharmaceutica Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.48 1.90 1.48 1.27 0.82

Basilea Pharmaceutica Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.17 2.01 1.04 1.00 0.88

Competitive Comparison of Basilea Pharmaceutica's Debt-to-Revenue

For the Biotechnology subindustry, Basilea Pharmaceutica's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Basilea Pharmaceutica's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Basilea Pharmaceutica's Debt-to-Revenue falls into.



Basilea Pharmaceutica Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Basilea Pharmaceutica's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(17.515 + 111.091) / 157.634
=0.82

Basilea Pharmaceutica's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(17.515 + 111.091) / 145.458
=0.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.


Basilea Pharmaceutica Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Basilea Pharmaceutica's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Basilea Pharmaceutica (XSWX:BSLN) Business Description

Traded in Other Exchanges
Address
Switzerland Innovation Park, Basel Area, Main Campus, Near Basel, Allschwil, CHE, 4058
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.

Basilea Pharmaceutica (XSWX:BSLN) Headlines

No Headlines